People | April 06, 2026
Dr Reddy’s elevates Saran PS as Head of Launch Excellence and Program Management
In his new role, Saran will spearhead the end-to-end launch framework for innovation-led portfolio
In his new role, Saran will spearhead the end-to-end launch framework for innovation-led portfolio
This strategic acquisition enables CORONA Remedies to penetrate deeper into targeted specialty and offer wider accessibility
The acquisition marks the company’s strategic entry into the fast-growing Hormone Replacement Therapy (HRT) segment and significantly strengthens its gynaecology portfolio in India
AVT03 is a biosimilar of Amgen's Prolia (denosumab 60 mg/mL) and Xgeva (denosumab 70 mg/mL), which are used to treat various bone conditions
Dr Reddy’s said scheme of amalgamation was carried with adherence to all the legal requirements including tax laws
Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
The total covered market size of four brands – Z&D, Pediclory, Pecef & Ezinapi combined is Rs 1800 crores
The integration and transition of the brands are expected to be completed by June 2022.
He has extensive leadership experience across supply chain and has worked at companies such as Unilever, Flipkart, Colgate-Palmolive & Mondelez
Subscribe To Our Newsletter & Stay Updated
